SCHEDULE 13G: Sabby Entities Disclose 4.9% Beneficial Ownership in Scinai Immunotherapeutics

Sabby Management, LLC, Sabby Volatility Warrant Master Fund Ltd, and Hal Mintz have jointly disclosed a 4.9% beneficial ownership stake in Scinai Immunotherapeutics Ltd. ADSs as of December 31, 2024.

Summary

• Sabby Management, LLC, Sabby Volatility Warrant Master Fund Ltd, and Hal Mintz have filed a Schedule 13G, reporting their beneficial ownership in Scinai Immunotherapeutics Ltd.
• As of December 31, 2024, the reporting persons collectively beneficially own 29,051 American Depositary Shares (ADSs) of Scinai Immunotherapeutics Ltd.
• This ownership represents 4.9% of the total outstanding class of Scinai Immunotherapeutics Ltd. ADSs.
• The reporting persons share both voting and dispositive power over all 29,051 ADSs.
• Sabby Management, LLC is a Delaware-based entity, Sabby Volatility Warrant Master Fund Ltd is based in the Cayman Islands, and Hal Mintz is a U.S. citizen residing in Florida.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It indicates a significant, but passive, investment by Sabby entities.

Positives

• The disclosure of a significant beneficial ownership stake by institutional investors like Sabby Management can signal confidence in the company's future prospects.
• The filing indicates a passive investment intent, as it is a Schedule 13G, not a Schedule 13D, meaning the shares were not acquired for the purpose of changing or influencing control of the issuer.

Negatives

• The 4.9% stake is just below the 5% threshold that would trigger a Schedule 13D filing, which requires more detailed disclosure about investment intent and potential plans regarding the issuer.

Risks

• The document itself does not introduce new risks but serves as a disclosure of ownership. The inherent risks associated with Scinai Immunotherapeutics Ltd. as a company remain unchanged by this filing.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding Scinai Immunotherapeutics Ltd.'s future performance or strategic direction.

Industry Context

This filing is a standard regulatory disclosure of beneficial ownership by an investment entity in a publicly traded company within the immunotherapeutics sector. It reflects an investment decision by Sabby entities but does not provide broader insights into industry trends or competitive landscape beyond the fact that Scinai Immunotherapeutics Ltd. is an active participant in this sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and trading activity.
• Company Management: Informs management of a notable passive investor holding a substantial portion of the company's ADSs.

Key Dates

Keywords

Scinai Immunotherapeutics, Schedule 13G, beneficial ownership, ADSs, Sabby Management, Sabby Volatility Warrant Master Fund, Hal Mintz, institutional ownership, SEC filing